Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The ...

Related Keywords

United States ,Chicago ,Illinois ,American ,Ciltacabtagene Autoleucel ,Hemophagocytic Lymphohistiocytosis ,Saadz Usmani ,Sen Zhuang ,Janssen Biotech Inc ,European Hematology Association Congress ,American Society Of Clinical Oncology ,European Hematology Association ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Congress Abstract ,American Society Of Clinical Oncology Annual Meeting ,United States Inc ,Clinical Research ,American Cancer Society ,None Of Janssen Biotech Inc ,Exchange Commission ,Companies Of Johnson ,European Medicines Agency ,Johnson ,Clinical Oncology ,Annual Meeting ,Confidence Interval ,Myeloma Service ,Memorial Sloan Kettering Cancer Center ,Earlier Lines ,Vice President ,Janssen Research ,Janssen Biotech ,Legend Biotech ,Important Safety ,Release Syndrome ,Effector Cell Associated Neurotoxicity Syndrome ,Macrophage Activation Syndrome ,Risk Evaluation ,Mitigation Strategy ,Nerve Palsies ,Recurrent Cytopenias ,Igg Hypersensitivity Reactions ,Use Machines ,Prescribing Information ,Boxed Warning ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Pharmaceutica ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Clinical Oncology Annual ,Refractory Multiple Myeloma ,Hematology Association ,Correlative Analyses ,Updated Clinical Data ,Statistics About Multiple Myeloma ,